Loading...
ROCO
4120
Market cap125mUSD
Oct 08, Last price  
46.00TWD
1D
0.44%
1Q
-2.95%
Jan 2017
-25.81%
IPO
88.83%
Name

Orient Europharma Co Ltd

Chart & performance

D1W1MN
ROCO:4120 chart
P/E
—
P/S
0.87
EPS
—
Div yield, %
2.17%
Shrs. gr., 5y
-0.09%
Rev. gr., 5y
-3.12%
Revenues
4.60b
+4.64%
6,093,253,0005,383,657,0004,767,028,0004,730,455,0004,591,894,0004,391,301,0004,595,102,000
Net income
-567m
L+99.83%
247,664,000199,303,000120,173,000-310,803,000143,943,000-283,934,000-567,391,000
CFO
-299m
L+146.58%
227,369,000608,549,00077,649,000-218,750,000120,980,000-121,108,000-298,634,000
Dividend
Jul 20, 20264 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, such as cardiovascular issues, metabolic disorders, neurological ailments, obstetric and gynecological health, respiratory diseases, andrological concerns, immunological responses, as well as antibiotics and anti-cancer therapies. Beyond prescription drugs, the company offers nutritional and infant care items, including specialized milk formulas and dietary supplements, marketed under the brand names Karihome, Babecare, and Ostricare. Additionally, it supplies health-related supplements, notably Buccotherm-branded thermal water, designed for the management of oral and periodontal conditions. The company's diverse product range extends to skincare, featuring items like essences, creams, lotions, eye creams, facial toners, and skin-repairing treatments available through its AGLab line. It also distributes skincare oils, body lotions, and gels for dry skin under the well-known Bio-Oil brand, and markets children's skincare solutions through the Mister Baby brand. Furthermore, OEP oversees ISISPHARMA, a dermatology laboratory dedicated to the creation and distribution of specialized dermo-cosmetic goods. Orient EuroPharma is actively involved in extensive research and development efforts, with several key compounds in its pipeline. These include Multikine, an immunotherapy treatment for head and neck cancer currently undergoing Phase III clinical trials; NC-6004, a platinum-based micelle chemotherapeutic agent also in Phase III; ASC-J9, a molecular chemical entity targeting androgen receptor degradation, which has successfully finished its Phase IIb clinical study; and 2ccPA, a phospholipid derivative for symptomatic knee osteoarthritis, progressing through Phase I clinical trials. Established in 1982, Orient EuroPharma Co., Ltd. maintains its headquarters in Taipei, Taiwan.

Key people

Jiaxiu Lin
General Manager-Greater China Area Nutrition & Health Business · since 2014
Jinzeng Lu
General Manager-Western Medicine Brand Development & New Business Division · since 2011
Jianming Tan
General Manager-Southeast Asia Area Nutrition & Health Business · since 2014
Pinjie Wang
Head of Finance & Accounting · since 2023
Su-fen Lin
Director · since 2019
General Manager, Director · since 2018
Chairman of the Board · since 2018
Junjie Wu
Director · since 2001
Chih-Cheng Chou
Independent Director · since 2025
Ching-Hsin Hsu
Independent Director · since 2025
Shui-Yung Lin
Independent Director · since 2025
Independent Director · since 2002
Jia-Cing Peng
Independent Director · since 2025
Independent Director · since 2002
IPO date
Nov 28, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT